Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: March 2026 (Transaction date: March 4, 2026; Expected closing: March 5, 2026)
Context: The Company entered into an inducement offer letter agreement with a holder of existing warrants to facilitate the exercise of those warrants at a reduced price in exchange for the issuance of new warrants.
Key Financial Metrics
- Expected Gross Proceeds: Approximately $4.0 million from the exercise of existing warrants.
- Transaction Volume: Exercise of 795,869 American Depositary Shares (ADSs).
- Reduced Exercise Price: $5.00 per ADS (reduced from the original $9.34 per ADS).
- Placement Agent Fees: 7.0% cash fee plus 1.0% management fee on gross proceeds; plus $75,000 for expenses and $15,950 for clearing fees.
- Placement Agent Warrants: 55,711 ADSs at an exercise price of $6.25 per ADS.
- New Warrants Issued: Up to 1,591,738 ADSs at an exercise price of $5.00 per ADS.
- Use of Proceeds: Funding research and development, clinical trials, working capital, and general corporate purposes.
Note: This filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period.
Material Changes
The primary material change is the capital raise transaction structured as a warrant inducement:
- Price Reduction: The exercise price for the existing warrants was reduced from $9.34 to $5.00 per ADS to induce the holder to exercise.
- Dilution: The Company is issuing new warrants covering 1,591,738 ADSs (double the number of shares being purchased) plus placement agent warrants, creating potential future dilution.
- Lock-up Restrictions: The Company agreed not to issue new ADSs or file other registration statements for 30 days after the effective date of the resale registration statement and is restricted from Variable Rate Transactions for one year post-closing.
Guidance, Outlook, and Risks
- Outlook: Proceeds are intended to support R&D and clinical trials.
- Contingencies: Closing is subject to customary conditions. The Company must file a resale registration statement (Form F-3) and have it declared effective within 90 days.
- Liquidity Risk: There is no established trading market for the new warrants, and the Company does not expect an active market to develop, resulting in extremely limited liquidity for these instruments.
- Forward-Looking Statements: The Company warns that the closing is not guaranteed and that forward-looking statements are subject to risks and uncertainties.
Investor Verification Checklist
- Verify the actual closing date and confirmation of the $4.0 million gross proceeds receipt.
- Confirm the effective date of the Resale Registration Statement (Form F-3) for the new warrant shares.
- Review the impact of the 1,591,738 new warrants and 55,711 placement agent warrants on fully diluted share count.
- Monitor the Company's cash burn rate relative to the new proceeds to assess runway for clinical trials.
- Check for any subsequent filings regarding the 30-day lock-up period on new issuances.